.png){kind=small}
Unlocking psychedelic medicine: a guide to accessing legal MDMA and psilocybin in Australia
May 15, 2021
Are you sitting comfortably? Then let's begin. Jump into the following content written for people like you. Or, go straight to the news feed for the latest updates from the world of psychedelics. Attend an event or meetup with other like-minded people. See what jobs are available in the psychedelic industry. Or, connect with a professional or an organisation by reaching out through our Organisations cluster list.
Legal access to psychedelic medicine, including psilocybin (magic mushrooms) and MDMA, for treating mental health disorders like PTSD and TRD, is now permitted in Australia. Access remains limited, requiring patients to navigate a complex and costly programs for around $20,000.
Australia remains ahead in legalising psychedelic-assisted therapy, as the FDA rejects Lykos’ MDMA for PTSD treatment.
Pill testing available at Victorian music festivals this summer and at a fixed site near Melbourne city centre from 2025.
This article discusses the risks of patient harm in psychedelic therapy and the unsettling revelation of misconduct allegations against a prominent figure.
The article explores the question of whether MDMA is a psychedelic drug. Research suggests that MDMA, while not producing trippy visuals, can impact brain connectivity similarly to hallucinogenic substances like LSD. Ultimately, the characterisation of MDMA as a psychedelic depends on the context.
A personal account of the first steps of someone's journey trying to access psychedelic therapy